A melanocyte lineage program confers resistance to MAP kinase pathway inhibition

Improved survival with vemurafenib in melanoma with BRAF V600E mutation

Chapman, P. B., Hauschild, A., Robert, C., Haanen, J. B., Ascierto, P., Larkin, J., Dummer, R., Garbe, C., Testori, A., Maio, M., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1103782 · Cited by 7,720

Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations

Flaherty, K. T., Infante, J. R., Daud, A., Gonzalez, R., Kefford, R. F., Sosman, J., Hamid, O., Schuchter, L., Cebon, J., Ibrahim, N., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1210093 · Cited by 2,810

Seven-transmembrane receptors

Pierce, K. L., Premont, R. T., & Lefkowitz, R. J. (2002) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm908 · Cited by 2,712

Improved Survival with MEK Inhibition in BRAF-Mutated Melanoma

Flaherty, K. T., Robert, C., Hersey, P., Nathan, P., Garbe, C., Milhem, M. M., Демидов, Л. В., Hassel, J. C., Rutkowski, P. L., Mohr, P., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1203421 · Cited by 2,205

Integrative genomic analyses identify MITF as a lineage survival oncogene amplified in malignant melanoma

Garraway, L. A., Widlund, H. R., Rubin, M. A., Getz, G., Berger, A. J., Ramaswamy, S., Beroukhim, R., Milner, D. A., Granter, S. R., Du, J., et al. (2005) · Nature · doi:10.1038/nature03664 · Cited by 1,548

COT drives resistance to RAF inhibition through MAP kinase pathway reactivation

Johannessen, C. M., Boehm, J. S., Kim, S. Y., Thomas, S. R., Wardwell, L., Johnson, L. A., Emery, C. M., Stransky, N., Cogdill, A. P., Barretina, J., et al. (2010) · Nature · doi:10.1038/nature09627 · Cited by 1,460

Improved survival with MEK Inhibition in BRAF-mutated melanoma for the METRIC Study Group

Flaherty, K. T., Robert, C., Hersey, P., Nathan, P., Garbe, C., Milhem, M. M., Демидов, Л. В., Hassel, J. C., Rutkowski, P. L., Mohr, P., et al. (2012) · Zurich Open Repository and Archive (University of Zurich) · doi:10.5167/uzh-63198 · Cited by 1,330

BRAF mutation predicts sensitivity to MEK inhibition

Solit, D. B., Garraway, L. A., Pratilas, C. A., Sawai, A., Getz, G. A., Basso, A., Ye, Q., Lobo, J. M., She, Y., Osman, I., et al. (2005) · Nature · doi:10.1038/nature04304 · Cited by 1,326

Raf-1 activates MAP kinase-kinase

Kyriakis, J. M., App, H., Zhang, X., Banerjee, P. T., Brautigan, D. L., Rapp, U. R., & Avruch, J. (1992) · Nature · doi:10.1038/358417a0 · Cited by 1,263

Mutations at the mouse microphthalmia locus are associated with defects in a gene encoding a novel basic-helix-loop-helix-zipper protein

Hodgkinson, C. A., Moore, K. J., Nakayama, A., Steingrı́msson, E., Copeland, N. G., Jenkins, N. A., & Arnheiter, H. (1993) · Cell · doi:10.1016/0092-8674(93)90429-t · Cited by 1,092

Systems biology analysis of mitogen activated protein kinase inhibitor resistance in malignant melanoma

Zecena, H., Tveit, D. M., Wang, Z., Farhat, A. M., Panchal, P., Liu, J., Singh, S. J., Sanghera, A., Bainiwal, A., Teo, S. Y., et al. (2018) · BMC Systems Biology · doi:10.1186/s12918-018-0554-1 · Cited by 36

Adaptive translational reprogramming of metabolism limits the response to targeted therapy in BRAFV600 melanoma

Smith, L. K., Parmenter, T. J., Kleinschmidt, M., Kusnadi, E. P., Kang, J., Martin, C. A., Lau, P. K. H., Patel, R. P., Lorent, J., Papadopoli, D. J., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-28705-x · Cited by 33

Phosphoproteomic Analysis of Cell-Based Resistance to BRAF Inhibitor Therapy in Melanoma

Parker, R., Vella, L. J., Xavier, D., Amirkhani, A., Parker, J., Cebon, J. S., & Molloy, M. P. (2015) · Frontiers in Oncology · doi:10.3389/fonc.2015.00095 · Cited by 33

Lithium and an EPAC-specific inhibitor ESI-09 synergistically suppress pancreatic cancer cell proliferation and survival

Wang, X., Luo, C., Cheng, X., & Lü, M. (2017) · Acta Biochimica et Biophysica Sinica · doi:10.1093/abbs/gmx045 · Cited by 33

Multi-modal molecular programs regulate melanoma cell state

Andrews, M. C., Oba, J., Wu, C., Zhu, H., Karpinets, T. V., Creasy, C. A., Forget, M., Yu, X., Song, X., Mao, X., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-31510-1 · Cited by 35

Epigenetic Mechanisms Regulating Adaptive Responses to Targeted Kinase Inhibitors in Cancer

Angus, S. P., Zawistowski, J. S., & Johnson, G. L. (2017) · The Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-010617-052954 · Cited by 32

MITF suppression improves the sensitivity of melanoma cells to a BRAF inhibitor

Aida, S., Sonobe, Y., Tanimura, H., Oikawa, N., Yuhki, M., Sakamoto, H., & Mizuno, T. (2017) · Cancer Letters · doi:10.1016/j.canlet.2017.09.008 · Cited by 33

Intrinsic Balance between ZEB Family Members Is Important for Melanocyte Homeostasis and Melanoma Progression

Bruneel, K., Verstappe, J., Vandamme, N., & Berx, G. (2020) · Cancers · doi:10.3390/cancers12082248 · Cited by 36

RAS pathway regulation in melanoma

Mahi, A. A., & Ablain, J. (2022) · Disease Models & Mechanisms · doi:10.1242/dmm.049229 · Cited by 33

Connecting the dots: Melanoma cell of origin, tumor cell plasticity, trans‐differentiation, and drug resistance

Castro‐Pérez, E., Singh, M. K., Sadangi, S., Mela‐Sánchez, C., & Setaluri, V. (2023) · Pigment Cell & Melanoma Research · doi:10.1111/pcmr.13092 · Cited by 33

Do Epigenetic Drug Treatments Hold the Key to Killing Cancer Progenitor Cells?

Byler, S., & Sarkar, S. (2014) · Epigenomics · doi:10.2217/epi.14.4 · Cited by 32

Advances in the relationship between AP-1 and tumorigenesis, development and therapy resistance

Xue, X., Li, Z., Zhao, J., Zhao, Z., Li, Z., Li, Y., Liu, Y., & He, H. (2025) · Discover Oncology · doi:10.1007/s12672-025-01783-1 · Cited by 31

New role of ID3 in melanoma adaptive drug-resistance

Sachindra, Larribère, L., Novak, D., Wu, H., Hüser, L., Granados, K., Orouji, E., & Utikal, J. S. (2017) · Oncotarget · doi:10.18632/oncotarget.22698 · Cited by 34

Enhancing the Efficacy of Melanocortin 1 Receptor-Targeted Radiotherapy by Pharmacologically Upregulating the Receptor in Metastatic Melanoma

Li, M., Liu, D., Lee, D., Kapoor, S., Gibson-Corley, K. N., Quinn, T. P., Sagastume, E. A., Mott, S. L., Walsh, S. A., Acevedo, M. R., et al. (2019) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.9b00512 · Cited by 32

CRISPR Screen Contributes to Novel Target Discovery in Prostate Cancer

Tsujino, T., Komura, K., Inamoto, T., & Azuma, H. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms222312777 · Cited by 31

Adaptive Responses as Mechanisms of Resistance to BRAF Inhibitors in Melanoma

Saei, A., & Eichhorn, P. J. A. (2019) · Cancers · doi:10.3390/cancers11081176 · Cited by 33

Primary cross-resistance to BRAFV600E-, MEK1/2- and PI3K/mTOR-specific inhibitors in BRAF-mutant melanoma cells counteracted by dual pathway blockade

Penna, I., Molla, A., Grazia, G., Cleris, L., Nicolini, G., Perrone, F., Picciani, B., Vecchio, M. D., de Braud, F., Mortarini, R., et al. (2015) · Oncotarget · doi:10.18632/oncotarget.6600 · Cited by 30

Computational Reconstruction of NFκB Pathway Interaction Mechanisms during Prostate Cancer

Börnigen, D., Tyekucheva, S., Wang, X., Rider, J. R., Lee, G. M., Mucci, L. A., Sweeney, C. J., & Huttenhower, C. (2016) · PLoS Computational Biology · doi:10.1371/journal.pcbi.1004820 · Cited by 30

Rare, functional, somatic variants in gene families linked to cancer genes: GPCR signaling as a paradigm

Raimondi, F., Inoue, A., Kadji, F. M. N., Ni, S., González‐Sánchez, J. C., Singh, G., de la Vega, A. A., Sotillo, R., Fischer, B., Aoki, J., et al. (2019) · Oncogene · doi:10.1038/s41388-019-0895-2 · Cited by 30

Second messenger Ap4A polymerizes target protein HINT1 to transduce signals in FcεRI-activated mast cells

Yu, J., Liu, Z., Liang, Y., Luo, F., Zhang, J., Tian, C., Motzik, A., Zheng, M., Kang, J., Zhong, G., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-12710-8 · Cited by 30

High-throughput methods for genome editing: the more the better

Huang, Y., Shang, M., Liu, T., & Wang, K. (2022) · PLANT PHYSIOLOGY · doi:10.1093/plphys/kiac017 · Cited by 32

Visual barcodes for clonal-multiplexing of live microscopy-based assays

Kaufman, T., Nitzan, E., Firestein, N., Ginzberg, M. B., Iyengar, S., Patel, N., Ben‐Hamo, R., Porat, Z., Hunter, J., Hilfinger, A., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-30008-0 · Cited by 30

CSE1L Links cAMP/PKA and Ras/ERK pathways and regulates the expressions and phosphorylations of ERK1/2, CREB, and MITF in melanoma cells

Lee, W., Shen, S., Wu, P., Chou, C., Shih, Y., Yeh, C., Yeh, K., & Jiang, M. (2015) · Molecular Carcinogenesis · doi:10.1002/mc.22407 · Cited by 31

BRAF-inhibitor Associated MEK Mutations Increase RAF-Dependent and -Independent Enzymatic Activity

Emery, C. M., Monaco, K., Wang, P., Balak, M. N., Freeman, A. K., Meltzer, J., Delach, S. M., Rakiec, D. P., Ruddy, D. A., Korn, J. M., et al. (2017) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-17-0211 · Cited by 30

The lincRNA MIRAT binds to IQGAP1 and modulates the MAPK pathway in NRAS mutant melanoma

Sanlorenzo, M., Vujic, I., Esteve‐Puig, R., Lai, K., Vujic, M., Lin, K. C., Posch, C., Dimon, M. T., Moy, A., Zekhtser, M., et al. (2018) · Scientific Reports · doi:10.1038/s41598-018-27643-3 · Cited by 30

Interferon α/β Enhances the Cytotoxic Response of MEK Inhibition in Melanoma

Litvin, O., Schwartz, S., Wan, Z., Schild, T., Rocco, M., Oh, N. L., Chen, B.-J., Goddard, N. L., Pratilas, C. A., & Pe’er, D. (2015) · Molecular Cell · doi:10.1016/j.molcel.2014.12.030 · Cited by 29

Novel combination strategies for enhancing efficacy of immune checkpoint inhibitors in the treatment of metastatic solid malignancies

Flynn, M. J., & Larkin, J. (2017) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2017.1369956 · Cited by 30

Melanoma‐associated GRM 3 variants dysregulate melanosome trafficking and cAMP signaling

Neto, A., & Ceol, C. J. (2017) · Pigment Cell & Melanoma Research · doi:10.1111/pcmr.12610 · Cited by 29

Significance of RB Loss in Unlocking Phenotypic Plasticity in Advanced Cancers

Venkadakrishnan, V. B., Yamada, Y., Weng, K., Idahor, O., & Beltran, H. (2023) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-23-0045 · Cited by 28

Transcription factors as critical players in melanoma invasiveness, drug resistance, and opportunities for therapeutic drug development

Cohen-Solal, K., Kaufman, H. L., & Lasfar, A. (2017) · Pigment Cell & Melanoma Research · doi:10.1111/pcmr.12666 · Cited by 30

Stem Cell-Derived Models of Neural Crest Are Essential to Understand Melanoma Progression and Therapy Resistance

Larribère, L., & Utikal, J. S. (2019) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2019.00111 · Cited by 29

The Role of Serotonin in Breast Cancer Stem Cells

Gwynne, W. D., Shakeel, M. S., Girgis-Gabardo, A., & Hassell, J. A. (2021) · Molecules · doi:10.3390/molecules26113171 · Cited by 28

In-depth genomic data analyses revealed complex transcriptional and epigenetic dysregulations of BRAF V600E in melanoma

Guo, X., Xu, Y., & Zhao, Z. (2015) · Molecular Cancer · doi:10.1186/s12943-015-0328-y · Cited by 28

FOXD3 Modulates Migration through Direct Transcriptional Repression of TWIST1 in Melanoma

Weiss, M. B., Abel, E. V., Dadpey, N., & Aplin, A. E. (2014) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-14-0170 · Cited by 27

Drug dependence in cancer is exploitable by optimally constructed treatment holidays

Maltas, J., Killarney, S. T., Singleton, K. R., Strobl, M. A. R., Washart, R., Wood, K. C., & Wood, K. B. (2023) · Nature Ecology & Evolution · doi:10.1038/s41559-023-02255-x · Cited by 27

Hsp90 as a “Chaperone” of the Epigenome

Isaacs, J. S. (2015) · Advances in cancer research · doi:10.1016/bs.acr.2015.09.003 · Cited by 28

Nuclear receptor function in skin health and disease: therapeutic opportunities in the orphan and adopted receptor classes

Yin, K., & Smith, A. G. (2016) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-016-2329-4 · Cited by 27

Extracellular Signal-Regulated Kinases: One Pathway, Multiple Fates

Deschênes‐Simard, X., Malleshaiah, M. K., & Ferbeyre, G. (2023) · Cancers · doi:10.3390/cancers16010095 · Cited by 27

MAPK pathway inhibition in melanoma: resistance three ways

Wellbrock, C. (2014) · Biochemical Society Transactions · doi:10.1042/bst20140020 · Cited by 29

POU4F1 promotes the resistance of melanoma to BRAF inhibitors through MEK/ERK pathway activation and MITF up-regulation

Liu, L., Yue, Q., Ma, J., Liu, Y., Zhao, T., Guo, W., Zhu, G., Guo, S., Wang, S., Gao, T., et al. (2020) · Cell Death and Disease · doi:10.1038/s41419-020-2662-2 · Cited by 26

Insight into molecular dynamics simulation of BRAF(V600E) and potent novel inhibitors for malignant melanoma

Chen, C. Y., & Tang, H. (2015) · International Journal of Nanomedicine · doi:10.2147/ijn.s80150 · Cited by 26

Systems analysis identifies miR-29b regulation of invasiveness in melanoma

Andrews, M. C., Cursons, J., Hurley, D., Anaka, M., Cebon, J. S., Behren, A., & Crampin, E. J. (2016) · Molecular Cancer · doi:10.1186/s12943-016-0554-y · Cited by 27

Applications of Genome-Wide Screening and Systems Biology Approaches in Drug Repositioning

Mohammadi, E., Benfeitas, R., Türkez, H., Borén, J., Nielsen, J., Uhlén, M., & Mardinoğlu, A. (2020) · Cancers · doi:10.3390/cancers12092694 · Cited by 25

Epigenetic modulation reveals differentiation state specificity of oncogene addiction

Khaliq, M., Manikkam, M., Martínez, E. D., & Fallahi‐Sichani, M. (2021) · Nature Communications · doi:10.1038/s41467-021-21784-2 · Cited by 27

A Framework of Major Tumor-Promoting Signal Transduction Pathways Implicated in Melanoma-Fibroblast Dialogue

Bellei, B., Migliano, E., & Picardo, M. (2020) · Cancers · doi:10.3390/cancers12113400 · Cited by 25

Integrated Analysis of the ETS Family in Melanoma Reveals a Regulatory Role of ETV7 in the Immune Microenvironment

Qu, H., Zhao, H., Zhang, X., Liu, Y., Li, F., Sun, L.-Y., & Song, Z. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.612784 · Cited by 24

Paneth-like transition drives resistance to dual targeting of KRAS and EGFR in colorectal cancer

Zhang, Y., Chen, J., She, Y., Fang, Z., Zhang, Y., Ruan, D., Guo, W., Liao, J., Zhou, W., Lao, J., et al. (2026) · Cancer Cell · doi:10.1016/j.ccell.2025.10.010 · Cited by 23

A unique hyperdynamic dimer interface permits small molecule perturbation of the melanoma oncoprotein MITF for melanoma therapy

Liu, Z., Chen, K., Dai, J., Xu, P. H., Sun, W. D., Liu, W., Zhao, Z., Bennett, S. P., Li, P., Ma, T., et al. (2023) · Cell Research · doi:10.1038/s41422-022-00744-5 · Cited by 23

Diverse array-designed modes of combination therapies in Fangjiomics

Liu, J. H., & Wang, Z. (2015) · Acta Pharmacologica Sinica · doi:10.1038/aps.2014.125 · Cited by 23

EPAC–RAP1 Axis-Mediated Switch in the Response of Primary and Metastatic Melanoma to Cyclic AMP

Rodríguez, C. I., Castro‐Pérez, E., Prabhakar, K., Block, L., Longley, B. J., Wisinski, J. A., Kimple, M. E., & Setaluri, V. (2017) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-17-0067 · Cited by 24

Src-Dependent DBL Family Members Drive Resistance to Vemurafenib in Human Melanoma

Feddersen, C. R., Schillo, J. L., Varzavand, A., Vaughn, H. R., Wadsworth, L. S., Voigt, A. P., Zhu, E. Y., Jennings, B. M., Mullen, S. A., Bobera, J., et al. (2019) · Cancer Research · doi:10.1158/0008-5472.can-19-0244 · Cited by 25

Cellular Reprogramming—A Model for Melanoma Cellular Plasticity

Granados, K., Poelchen, J., Novak, D., & Utikal, J. S. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21218274 · Cited by 23

Overcoming MITF-conferred drug resistance through dual AURKA/MAPK targeting in human melanoma cells

Pathria, G., Garg, B., Borgdorff, V., Garg, K., Wagner, C., Superti‐Furga, G., & Wagner, S. N. (2016) · Cell Death and Disease · doi:10.1038/cddis.2015.369 · Cited by 23

Targeting Notch enhances the efficacy of ERK inhibitors in BRAF-V600E melanoma

Krepler, C., Xiao, M., Samanta, M., Vultur, A., Chen, H., Brafford, P. A., Reyes-Uribe, P. I., Halloran, M. B., Chen, T., He, X., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.12078 · Cited by 23

Profile of selumetinib and its potential in the treatment of melanoma

Patel, S. P., & Kim, D. W. (2014) · OncoTargets and Therapy · doi:10.2147/ott.s51596 · Cited by 23

Bromodomain and extra-terminal domain (BET) proteins regulate melanocyte differentiation

Trivedi, A. R., Mehrotra, A., Baum, C. E., Lewis, B., Basuroy, T., Blomquist, T. M., Trumbly, R. J., Filipp, F. V., Setaluri, V., & de la Serna, I. L. (2020) · Epigenetics & Chromatin · doi:10.1186/s13072-020-00333-z · Cited by 22

Estradiol differently affects melanin synthesis of malignant and normal melanocytes: a relationship with clock and clock-controlled genes

Poletini, M. O., de Assis, L. V. M., Moraes, M. N., & Castrucci, A. M. D. L. (2016) · Molecular and Cellular Biochemistry · doi:10.1007/s11010-016-2781-3 · Cited by 22

Functional interplay between secreted ligands and receptors in melanoma

Herráiz, C., Jiménez‐Cervantes, C., Sánchez‐Laorden, B. L., & García-Borrón, J. C. (2017) · Seminars in Cell and Developmental Biology · doi:10.1016/j.semcdb.2017.06.021 · Cited by 22

MEK inhibition remodels the active chromatin landscape and induces SOX10 genomic recruitment in BRAF(V600E) mutant melanoma cells

Program, N. C. S., Fufa, T., Baxter, L. L., Wedel, J. C., Gildea, D. E., Loftus, S. K., & Pavan, W. J. (2019) · Epigenetics & Chromatin · doi:10.1186/s13072-019-0297-2 · Cited by 24

ABCB5 is activated by MITF and β‐catenin and is associated with melanoma differentiation

Louphrasitthiphol, P., Chauhan, J. S., & Goding, C. R. (2019) · Pigment Cell & Melanoma Research · doi:10.1111/pcmr.12830 · Cited by 22

Kinome Profiling to Predict Sensitivity to MAPK Inhibition in Melanoma and to Provide New Insights into Intrinsic and Acquired Mechanism of Resistance

Krayem, M., Aftimos, P. G., Najem, A., van den Hooven, T., van den Berg, A., Hovestad-Bijl, L., de Wijn, R., Hilhorst, R., Ruijtenbeek, R., Sabbah, M., et al. (2020) · Cancers · doi:10.3390/cancers12020512 · Cited by 22

The pleiotropic roles of circular and long noncoding RNAs in cutaneous melanoma

Montico, B., Giurato, G., Pecoraro, G., Salvati, A., Covre, A., Colizzi, F., Steffan, A., Weisz, A., Maio, M., Sigalotti, L., et al. (2021) · Molecular Oncology · doi:10.1002/1878-0261.13034 · Cited by 22

Linalool inhibits the growth of human T cell acute lymphoblastic leukemia cells with involvement of the MAPK signaling pathway

Gong, X., Wang, B., Yan, L., Lu, X., & Zhao, X. (2020) · Oncology Letters · doi:10.3892/ol.2020.12042 · Cited by 21

MC 1R and NR 4A receptors in cellular stress and DNA repair: implications for UVR protection

Yin, K., Sturm, R. A., & Smith, A. G. (2014) · Experimental Dermatology · doi:10.1111/exd.12420 · Cited by 22

Discovery of a Synergistic Inhibitor of cAMP-Response Element Binding Protein (CREB)-Mediated Gene Transcription with 666 - 15

Xie, F., Fan, Q., Li, B. X., & Xiao, X. (2019) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.9b01207 · Cited by 21

Targeting GPCRs and Their Signaling as a Therapeutic Option in Melanoma

Raymond, J. H., Aktary, Z., Larue, L., & Delmas, V. (2022) · Cancers · doi:10.3390/cancers14030706 · Cited by 20

Tumor Cell Resistance to the Inhibition of BRAF and MEK1/2

Chen, W., & Park, J. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241914837 · Cited by 21

Raf‐interactome in tuning the complexity and diversity of Raf function

An, S., Yang, Y., Ward, R. J., Liu, Y., Guo, X., & Xu, T. (2014) · FEBS Journal · doi:10.1111/febs.13113 · Cited by 20

Interleukin-like EMT inducer regulates partial phenotype switching in MITF-low melanoma cell lines

Noguchi, K., Dalton, A. C., Howley, B. V., McCall, B. J., Yoshida, A., Diehl, J. A., & Howe, P. H. (2017) · PLoS ONE · doi:10.1371/journal.pone.0177830 · Cited by 23

Linking CREB function with altered metabolism in murine fibroblast-based model cell lines

Steven, A., Leisz, S., Wickenhauser, C., Schulz, K., Mougiakakos, D., Kiessling, R. W., Denkert, C., & Seliger, B. (2017) · Oncotarget · doi:10.18632/oncotarget.22135 · Cited by 20

Combined MAPK Pathway and HDAC Inhibition Breaks Melanoma

Lombard, D. B., Cierpicki, T., & Grembecka, J. E. (2019) · Cancer Discovery · doi:10.1158/2159-8290.cd-19-0069 · Cited by 20

Modelling of Protein Kinase Signaling Pathways in Melanoma and Other Cancers

Kunz, M., & Vera, J. (2019) · Cancers · doi:10.3390/cancers11040465 · Cited by 21

Antagonists of the serotonin receptor 5A target human breast tumor initiating cells

Gwynne, W. D., Shakeel, M. S., Girgis-Gabardo, A., Kim, K. H., Ford, E., Dvorkin‐Gheva, A., Aarts, C. W., Isaac, M. B., Al‐awar, R., & Hassell, J. A. (2020) · BMC Cancer · doi:10.1186/s12885-020-07193-6 · Cited by 20

Advanced Melanoma

Haugh, A. M., Salama, A. K. S., & Johnson, D. B. (2020) · Hematology/Oncology Clinics of North America · doi:10.1016/j.hoc.2020.09.005 · Cited by 20

SATB2 induction of a neural crest mesenchyme-like program drives melanoma invasion and drug resistance

Fazio, M., van Rooijen, E., Dang, M., van de Hoek, G., Ablain, J., Mito, J. K., Yang, S. P., Thomas, A., Jonathan, M., Fabo, T., et al. (2021) · eLife · doi:10.7554/elife.64370 · Cited by 20

SWI/SNF Chromatin Remodeling Enzymes in Melanoma

Dreier, M. R., & de la Serna, I. L. (2022) · Epigenomes · doi:10.3390/epigenomes6010010 · Cited by 20

The CoREST repressor complex mediates phenotype switching and therapy resistance in melanoma

Wu, M., Hanly, A. M., Gibson, F. T., Fisher, R. J., Rogers, S., Park, K., Zuger, A., Kuang, K., Kalin, J. H., Nocco, S. E., et al. (2024) · Journal of Clinical Investigation · doi:10.1172/jci171063 · Cited by 22

KITD816V Induces SRC-Mediated Tyrosine Phosphorylation of MITF and Altered Transcription Program in Melanoma

Phung, B., Kazi, J. U., Lundby, A., Bergsteinsdóttir, K., Sun, J., Goding, C. R., Jönsson, G. B., Olsen, J. V., Steingrı́msson, E., & Rönnstrand, L. (2017) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-17-0149 · Cited by 19

JUNB promotes the survival of Flavopiridol treated human breast cancer cells

Hicks, M. J., Hu, Q., Macrae, E. R., & DeWille, J. W. (2014) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2014.05.057 · Cited by 19

Integrating phenotypic small-molecule profiling and human genetics: the next phase in drug discovery

Johannessen, C. M., Clemons, P. A., & Wagner, B. K. (2014) · Trends in Genetics · doi:10.1016/j.tig.2014.11.002 · Cited by 18

A nuclear cAMP microdomain suppresses tumor growth by Hippo pathway inactivation

Drozdz, M. M., Doane, A. S., Alkallas, R., Desman, G. T., Bareja, R., Reilly, M., Bang, J., Yusupova, M., You, J., Eraslan, Z., et al. (2022) · Cell Reports · doi:10.1016/j.celrep.2022.111412 · Cited by 18

Lineage-coupled clonal capture identifies clonal evolution mechanisms and vulnerabilities of BRAFV600E inhibition resistance in melanoma

Zhang, Z.-Y., Ding, Y., Ezhilarasan, R., Lhakhang, T. W., Wang, Q., Yang, J., Modrek, A. S., Zhang, H., Tsirigos, A., Futreal, P. A., et al. (2022) · Cell Discovery · doi:10.1038/s41421-022-00462-7 · Cited by 18

A compendium of Amplification-Related Gain Of Sensitivity genes in human cancer

Rendo, V., Schubert, M., Khuu, N., Rodríguez, M. F. S. P., Whyte, D., Ling, X., van den Brink, A., Huang, K., Swift, M. L., He, Y. J., et al. (2025) · Nature Communications · doi:10.1038/s41467-025-56301-2 · Cited by 20

Crosstalk signaling in targeted melanoma therapy

Meierjohann, S. (2017) · Cancer and Metastasis Reviews · doi:10.1007/s10555-017-9659-z · Cited by 20

Joint action of miR‐126 and MAPK/PI3K inhibitors against metastatic melanoma

Pedini, F., Luca, G. D., Felicetti, F., Puglisi, R., Boe, A., Arasi, M. B., Fratini, F., Mattia, G., Spada, M., Caporali, S., et al. (2019) · Molecular Oncology · doi:10.1002/1878-0261.12506 · Cited by 18

Parthenolide induces MITF-M downregulation and senescence in patient-derived MITF-Mhigh melanoma cell populations

Hartman, M. L., Talar, B., Sztiller-Sikorska, M., Nejc, D., & Czyż, M. (2016) · Oncotarget · doi:10.18632/oncotarget.7030 · Cited by 17

Regulation of CEACAM1 Protein Expression by the Transcription Factor ETS-1 in BRAF-Mutant Human Metastatic Melanoma Cells

Kfir-Elirachman, K., Ortenberg, R., Vizel, B., Besser, M. J., Barshack, I., Schachter, J., Nemlich, Y., & Markel, G. (2018) · Neoplasia · doi:10.1016/j.neo.2018.01.012 · Cited by 17

Interleukin-like EMT inducer (ILEI) promotes melanoma invasiveness and is transcriptionally up-regulated by upstream stimulatory factor-1 (USF-1)

Noguchi, K., Dincman, T. A., Dalton, A. C., Howley, B. V., McCall, B. J., Mohanty, B. K., & Howe, P. H. (2018) · Journal of Biological Chemistry · doi:10.1074/jbc.ra118.003616 · Cited by 17

miR-524-5p reduces the progression of the BRAF inhibitor-resistant melanoma

Nguyen, M.-H., Lin, C.-H., Liu, S., Miyashita, A., Ihn, H., Lin, H., Ng, C., Tsai, J.-C., Chen, M., Tsai, M.-S., et al. (2020) · Neoplasia · doi:10.1016/j.neo.2020.10.009 · Cited by 17

Dimethyl Fumarate Combined With Vemurafenib Enhances Anti-Melanoma Efficacy via Inhibiting the Hippo/YAP, NRF2-ARE, and AKT/mTOR/ERK Pathways in A375 Melanoma Cells

Li, H., Wang, Y., Su, R., Jia, Y., Lai, X., Su, H., Fan, Y., Wang, Y., Xing, W., & Qin, J. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.794216 · Cited by 17

Scrotal angiokeratoma (Fordyce): histopathological and ultrastructural findings.

Gioglio, L., Porta, C., Moroni, M., Nastasi, G., & Gangarossa, I. (1992) · PubMed · Cited by 17

Melanoma genome evolution across species

Kansler, E. R., Verma, A., Langdon, E. M., Simon-Vermot, T., Yin, A., Lee, W., Attiyeh, M. A., Elemento, O., & White, R. M. (2017) · BMC Genomics · doi:10.1186/s12864-017-3518-8 · Cited by 17

A New Bioassay Platform Design for the Discovery of Small Molecules with Anticancer Immunotherapeutic Activity

Gallo, C., Barra, G., Saponaro, M., Manzo, E., Fioretto, L., Ziaco, M., Nuzzo, G., d’Ippolito, G., Palma, R. D., & Fontana, A. (2020) · Marine Drugs · doi:10.3390/md18120604 · Cited by 16

Dual c-JunN-terminal kinase-cyclin D1 and extracellular signal-related kinase-c-Jun disjunction in human melanoma

Pathria, G., Garg, B., Garg, K., Wagner, C., & Wagner, S. N. (2016) · British Journal of Dermatology · doi:10.1111/bjd.14713 · Cited by 17

Support for phosphoinositol 3 kinase and mTOR inhibitors as treatment for lupus using in-silico drug-repurposing analysis

Toro‐Domínguez, D., Carmona‐Sáez, P., & Alarcón-Riquelme, M. E. (2017) · Arthritis Research & Therapy · doi:10.1186/s13075-017-1263-7 · Cited by 16

Targeted Therapy-Resistant Melanoma Cells Acquire Transcriptomic Similarities with Human Melanoblasts

Larribère, L., Kuphal, S., Sachpekidis, C., Sachindra, Hüser, L., Bosserhoff, A., & Utikal, J. S. (2018) · Cancers · doi:10.3390/cancers10110451 · Cited by 17

Active receptor tyrosine kinases, but not Brachyury, are sufficient to trigger chordoma in zebrafish

D‘Agati, G., Cabello, E. M., Frontzek, K., Rushing, E. J., Klemm, R. W., Robinson, M. D., White, R. M., Mosimann, C., & Burger, A. (2019) · Disease Models & Mechanisms · doi:10.1242/dmm.039545 · Cited by 16

Androgen-Independent Prostate Cancer Is Sensitive to CDC42-PAK7 Kinase Inhibition

Han, H. H., Park, C. K., Choi, Y. D., Cho, N. H., Lee, J. S., & Cho, K. S. (2022) · Biomedicines · doi:10.3390/biomedicines11010101 · Cited by 15

MITF depletion elevates expression levels of ERBB3 receptor and its cognate ligand NRG1-beta in melanoma

Alver, T. N., Lavelle, T. J., Longva, A. S., Øy, G. F., Hovig, E. J., & Bøe, S. L. (2016) · Oncotarget · doi:10.18632/oncotarget.10422 · Cited by 15

Abstract PR10: A cyclic AMP-regulated melanocyte lineage program confers resistance to MAP kinase pathway inhibition

Johannessen, C. M., Johnson, L. A., Piccioni, F., Townes, A., Frederick, D. T., Flaherty, K. T., Wargo, J. A., Root, D. E., & Garraway, L. A. (2013) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.pms-pr10 · Cited by 1

Melanocytic Signaling Promotes Resistance to MAPK Inhibition

(2013) · Cancer Discovery · doi:10.1158/2159-8290.cd-rw2013-252

Abstract IA8: BRAF and MEK resistance in melanoma

Herlyn, M., & Villanueva, J. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.mechres-ia8

Resistance to MAPK inhibition: come see(c) AMP ed up melanoma

Rodríguez, C. I., & Setaluri, V. (2014) · Pigment Cell & Melanoma Research · doi:10.1111/pcmr.12230 · Cited by 1

Targeting mTOR signaling overcomes acquired resistance to combined BRAF and MEK inhibition in BRAF-mutant melanoma

Wang, B., Zhang, W., Zhang, G., Kwong, L., Lu, H., Tan, J., Sadek, N., Xiao, M., Zhang, J., Labrie, M., et al. (2021) · Oncogene · doi:10.1038/s41388-021-01911-5 · Cited by 66